seiji hoshi

Dr. seiji hoshi

Urology, Fukushima Medical University, Fukushima, Japan
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
SHseiji hoshi
seiji hoshi
KYKei Yaginuma
Kei Yaginuma
SMSatoru Meguro
Satoru Meguro
AOAkifumi Onagi
Akifumi Onagi
KMKanako Matsuoka
Kanako Matsuoka
YKYoshiyuki Kojima
Yoshiyuki Kojima
Theranostics (therapy + diagnosis) targeting prostate-specific membrane antigen (PSMA) is an emerging therapeutic modality that could alter treatment strategies for prostate cancer. Although PSMA-targeted radioligand therapy (PSMA-RLT) has a highly therapeutic effect on PSMA-positive tumor tissue, the efficacy of PSMA-RLT depends on PSMA expression. Moreover, predictors of treatment response other than PSMA expression are under investigation. Therefore, the optimal patient population for PSMA-RLT remains unclear. This review provides an overview of the current status of theranostics for prostate cancer, focusing on PSMA ligands. In addition, we summarize various findings regarding the efficacy and problems of PSMA-RLT and discuss the optimal patient for PSMA-RLT.

22 February 2021 in Cancer Science
Verified
Journal Article
Open access
PDF file
SHseiji hoshi
seiji hoshi
SMSatoru Meguro
Satoru Meguro
HIHitomi Imai
Hitomi Imai
YMYuta Matsuoka
Yuta Matsuoka
YYYuki Yoshida
Yuki Yoshida
YKYoshiyuki Kojima
Yoshiyuki Kojima
Enzalutamide (Enz) is a second‐generation androgen receptor (AR) antagonist for castration‐resistant prostate cancer (CRPC) therapy, and it prolongs survival time in these patients. However, during Enz treatment, CRPC patients usually acquire resistance to Enz and often show cross‐resistance to other AR signaling inhibitors. Although glucocorticoid receptor (GR) is involved in this resistance, the role of GR has not yet been clarified. Here, we report that chronic Enz treatment induced GR‐mediated glucose transporter 4 (GLUT4) upregulation, and that upregulation was associated with resistance to Enz and other AR signaling inhibitors. Additionally, inhibition of GLUT4 suppressed cell proliferation in Enz‐resistant prostate cancer cells, which recovered from Enz resistance and cross‐resistance without changes in GR expression. Thus, a combination of Enz and a GLUT4 inhibitor could be useful in Enz‐resistant CRPC patients.

14 November 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
KMKanako Matsuoka
Kanako Matsuoka
HAHidenori Akaihata
Hidenori Akaihata
JHJunya Hata
Junya Hata
RTRyo Tanji
Ryo Tanji
RHRuriko Honda-Takinami
Ruriko Honda-Takinami
YKYoshiyuki Kojima
Yoshiyuki Kojima
Chronic sympathetic hyperactivity is known to affect metabolism and cause various organ damage including bladder dysfunction. In this study, we evaluated whether l-theanine, a major amino acid found in green tea, ameliorates bladder dysfunction induced by chronic sympathetic hyperactivity as a dietary component for daily consumption. Spontaneously hypertensive rats (SHRs), as an animal model of bladder dysfunction, were divided into SHR–water and SHR–theanine groups. After 6 weeks of oral administration, the sympathetic nervous system, bladder function, and oxidative stress of bladder tissue were evaluated. The mean blood pressure, serum noradrenaline level, and media-to-lumen ratio of small arteries in the suburothelium were significantly lower in the SHR–theanine than in the SHR–water group. Micturition interval was significantly longer, and bladder capacity was significantly higher in the SHR–theanine than in the SHR–water group. Bladder strip contractility was also higher in the SHR–theanine than in the SHR–water group. Western blotting of bladder showed that expression of malondialdehyde was significantly lower in the SHR–theanine than in the SHR–water group. These results suggested that orally administered l-theanine may contribute at least partly to the prevention of bladder dysfunctions by inhibiting chronic sympathetic hyperactivity and protecting bladder contractility.

28 July 2018 in Journal of Urology
Verified
Journal Article
Closed access
PDF file
YKYoshiyuki Kojima
Yoshiyuki Kojima
TKTomoyuki Koguchi
Tomoyuki Koguchi
KMKentaro Mizuno
Kentaro Mizuno
YSYuichi Sato
Yuichi Sato
SHseiji hoshi
seiji hoshi
KMKoichi Matsuda
Koichi Matsuda
We evaluated the association of hypospadias with 17 susceptibility loci previously identified by a European genome-wide association study (GWAS) in Japanese patients. We also examined the expression of candidate genes in male mouse embryos to discuss the possible underlying mechanisms of this disease. We enrolled 169 Japanese patients (mean age at surgery: 3.7 years) who underwent repair of hypospadias. Genotyping of 17 SNPs was performed by using a multiplex-polymerase chain reaction (PCR) invader assay. We also performed in situ hybridization to determine whether candidate genes were expressed in the male genital tubercle during embryonic development of the external genitalia in mice. SNP rs3816183 of HAAO was significantly associated with susceptibility to hypospadias in general (p=0.0019) and both anterior/middle hypospadias (p=0.0283) and posterior hypospadias (p=0.0226), while SNP rs6499755 of IRX6 showed an association with susceptibility to anterior/middle hypospadias (p=0.0472). In mouse embryos, there was no significant upregulation of Haao expression in the developing male external genitalia. Irx3 and Irx5, which are linked to Irx6 within the IrxB cluster, were expressed in the mesenchyme remote from the urethral plate epithelium during the critical embryonic period for masculinization. Irx6 was expressed in the ectodermal epithelium, showing prominent dorsal ectodermal expression without expression in ventral ectoderm adjacent to the urethral plate during the same period. Genetic variations of HAAO and IRX6 influence susceptibility to hypospadias in Japanese population, although further study will be needed to clarify the mechanism by which contributes to the pathogenesis of hypospadias.

13 June 2000 in Urological Research
Verified
Journal Article
Closed access
PDF file
ISI. Shintaku
I. Shintaku
NKN. Kawagoe
N. Kawagoe
SYS. Yutani
S. Yutani
SHseiji hoshi
seiji hoshi
SOS. Orikasa
S. Orikasa
KIK. Itoh
K. Itoh

18 August 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
SMSatoru Meguro
Satoru Meguro
SMSyunta Makabe
Syunta Makabe
KYKei Yaginuma
Kei Yaginuma
AOAkifumi Onagi
Akifumi Onagi
RTRyo Tanji
Ryo Tanji
YKYoshiyuki Kojima
Yoshiyuki Kojima
Since cancer is often linked to the aging process, the importance of cellular senescence in cancer has come under the spotlight. While senescence in cancer cells can serve as a natural barrier against cancer due to its proliferation arrest, its secretory phenotypes and alterations in the surface proteome can paradoxically promote or suppress tumor progression. Senescent cancer-associated fibroblasts, endothelial cells, and immune cells can also contribute to cancer promotion. During therapeutic interventions for cancer, not only their therapeutic effects, but also therapy-induced senescence may have an impact on cancer outcomes. Senotherapeutics, therapy targeting senescent cells, have been reported as novel cancer therapy in recent studies, and the combination of senescence induction and senotherapeutics has been increasingly recognized. Although some clinical trials of senotherapeutic drugs for cancer with or without senescence-inducible therapy are ongoing, there is as yet no satisfactory clinical application. With further research into targeting senescence in oncology, it is expected that senotherapeutics, particularly in combination with senescence-inducing therapy, will become a novel therapeutic strategy.